Emergingby GlyphAbbVie ends its decade-long partnership with Calico
AbbVie ended the aging research alliance and laid off chemists working on it.
Longevity biotechstatnews.com
AbbVie
Public companyUSfounded 20132 fields
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechPartnered with Calico on aging drug research for over a decade before ending the alliance in 2025. | Partnered with Calico on aging drug research for over a decade before ending the alliance in 2025. | statnews.com |
| NanotechnologyBought Capstan's in vivo tLNP CAR-T program for $2.1 billion in cash. | Bought Capstan's in vivo tLNP CAR-T program for $2.1 billion in cash. | sec.gov |
Events
About
- Source
- statnews.com (press, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
AbbVie
Joined in Nanotechnology. Bought Capstan's in vivo tLNP CAR-T program for $2.1 billion in cash.
AbbVie
Joined in Longevity biotech. Partnered with Calico on aging drug research for over a decade before ending the alliance in 2025.
AbbVie
Added in Longevity biotech. Partnered with Calico on aging drug research for over a decade before ending the alliance in 2025.